MPN Chronicles Podcast – 05, Tips to healthy living with a Myeloproliferative Neoplasm by David Wallace It’s important for us, as patients to do everything we can naturally to help our body fight MPNs. Here are a few tips: • Eating right, a balanced diet is especially important if you have an MPN as eating […]
MPNs and Insomnia: Tips for Better Sleep
August 18, 2019 By
65% of Myeloproliferative Neoplasm, Cancer Patients report Sleep Problems Part 5 in a New Series – “Addressing MPN Symptoms” (2019) by Heidi Cascarano Many people struggle with sleep disturbances, and we all know that lack of quality sleep can lead to daytime fatigue, diminished quality of life, and other health problems. What’s worse is that […]
Inrebic (Fedratinib) receives FDA Approval for Myelofibrosis
August 16, 2019 By
The First New Treatment in Nearly a Decade for MF Patients INREBIC provides new, once-daily oral option for patients affected by rare bone marrow cancer SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or […]
Chronic Pain in Over 50 percent of MPN Cancer patients
August 15, 2019 By
Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States Part 4 in a New Series – “Addressing MPN Symptoms” (2019) Jiang C, Wang H, Wang Q, Luo Y, Sidlow R, Han X. Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States. JAMA Oncol. Published […]
Targeted therapies for Myeloproliferative Neoplasms MPNs
July 24, 2019 By
Abstract The discovery of JAK2V617F and the demonstration that BCR-ABL-negative myeloproliferative neoplasms (MPNs) are driven by abnormal JAK2 activation have led to advances in diagnostic algorithms, prognosis and ultimately also treatment strategies. The JAK 1/2 inhibitor ruxolitinib was a pivotal moment in the treatment of MPNs, representing the first targeted treatment in this field. Despite a […]
Nutrition and Diet May Reduce Chronic Inflammation while Improving Symptom Burden in MPN Patients
July 14, 2019 By
Nutrition for MPN Patients Part 3 in a New Series – “Addressing MPN Symptoms” (2019) We know diet plays a role in inflamation. Chronic inflammation may be an important driving force for clonal evolution and disease progression in myeloproliferative neoplasms (MPNs), essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF). So with that in mind, eating a […]
What I Learned from going through Stem Cell Transplant for Myelofibrosis
June 13, 2019 By
No Time Like the Present – To Kick Cancer’s Butt by Heidi Cascarano It wasn’t in the plans. I had lived with the diagnosis of Polycythemia Vera, and then Myelofibrosis for 9 years. I was told I could live several years with them and that progression was the exception. My hope was amplified by my […]
Ten Year Anniversary Living with Polycythemia Vera Blood Cancer
June 2, 2019 By
Inspire by Living! by David Wallace Your numbers do NOT always reflect how you feel, so important to remember! I’ve felt like crap before and my numbers were good. How you feel is one of the most important measurement criteria, in my opinion. Counts were off on my last heme visit, about a month ago, […]
Polycythemia Vera Brain Fog
April 7, 2019 By
MPN Symptom Uncovered Part 2 in a New Series – “Addressing MPN Symptoms” (2019) by David Wallace This is no great “epiphany moment” article, just a quick report on a real myeloproliferative neoplasm (MPN) symptom I experience from time to time. Most mornings, I make a healthy smoothie to get me up and rolling. This […]
Celgene’s Fedratinib Given FDA Priority Review for New Drug Application in Myelofibrosis
March 5, 2019 By
PV Reporter was first to break the news on the Expanded Access Program for Fedratinib for Myelofibrosis Patients on November 16th, 2018. The next logical step for Celgene was filing for New Drug Application – Granted by the FDA on March 5th, 2019 Celgene Corporation announced today the U.S. Food and Drug Administration has accepted […]
